Digital Transformations as a Key Enabler to Strengthen Research in Biosimilars Industry
The potential for digital & analytics applications in the pharmaceutical and biotechnology sector has grown dramatically in recent years as a result of fast technological advances as well as changes in the market environment & stakeholder behaviour as a result of the pandemic. Digital transformation has the potential to provide substantial advantages to the biosimilars industry across the value chain.
On the front end, technology has already played an important role in keeping the industry, health care providers, and pharmacists connected in the face of limited physical contacts. Traditional, face-to-face detailing-based commercial methods are increasingly and are being supplemented with digital engagement models, and this trend is expected to continue. This will not only allow the industry to deepen connections and thus increase biosimilar medicine adoption, but it will also provide an economically viable option for rapidly expanding reach into territories that would otherwise remain untapped due to constraints of the representative-based economic model.
At the backend, digital and analytics have the ability to significantly increase capacity by improving efficiency, quality results, and creating a zero-deviation environment. Through the use of simulations and in-silico batch modelling, drug development and product transfers processes would pick up speed in future.
Growing Prevalence of Lifestyle Diseases Anticipated to Fuel European Biosimilars Market Growth
Since biosimilars do not need significant research and testing, they are less costly than their branded equivalents. This saves both money and time, thus leading to reduction in overall price of the respective biosimilar. They also have short marketing periods since biosimilars do not need significant marketing because their branded equivalents' safety and effectiveness profiles have previously been established. During the forecast period, many blockbuster biologics are anticipated to lose their patent protection. Biosimilar producers are anticipated to benefit greatly from the expiry of patents and other intellectual property rights. The European population is ageing, with approximately one-fifth of the population above 65 years which represents a substantial rise in the burden of lifestyle illnesses. Moreover, the incidence of illnesses such as diabetes, autoimmune disorders, cancer, and others are on rise. Due to increasing healthcare costs, governments in a number of European nations have enacted laws encouraging doctors, pharmacists, and patients to choose biosimilars over branded biologics.
Biosimilar drugs provide a significant potential with significant advantages, since they save money throughout Europe, contribute to the long-term viability of national healthcare systems, and enhance patient access to cutting-edge therapies. However, to realize these benefits over the course of long run, the market for biosimilar medicines must remain viable.
The global biosimilars and follow-on biologics is segmented on the basis of type of manufacturing into in-house, and CMOs segment. In-house segment dominated the global biosimilars market by manufacturing with a share of over 70% in 2020 .The in-house segment is projected to witness highest growth owing robust R&D infrastructure of major companies which closely work with their strategic partners.
The global biosimilars and follow-on biologics is segmented on the basis of type into monoclonal antibodies, fusion proteins, insulin, erythropoietin, granulocyte-colony stimulating factor, interferon, growth hormones, fertility hormones, and others. Monoclonal antibodies segment holds majority of the market share and was valued at US$8,910.0 million in 2020 growing at a CAGR of 30.84% from 2021 to 2031.
On the basis of application, the global biosimilars and follow-on biologics is segmented blood disorders, oncology diseases, chronic & autoimmune diseases, growth hormone deficiencies, and others. Oncology diseases segment held majority of the market share and was valued at US$3,704.8 million in 2020. The segment is expected to the highest growth rate during the forecast period.
According to our analysis, European region is a leader in the global biosimilars and follow-on biologics market. European biosimilars and follow-on biologics market was valued at US$5,308.0 million in 2020. This regional market growth has been fuelled by well-developed healthcare infrastructure and an increasing number of product releases.
What are the Market Trends for Global Biosimilars and Follow-on Biologics R&D Market?
• Regulatory Hurdles Slowing Down Access to Biosimilars
• Vulnerability of Global Pharmaceutical Manufacturing Amid COVID-19
• Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
• Digital Transformations as a Key Enabler to Strengthen Research in Biosimilars Industry
Discover how to stay ahead
Our 570+ page report provides 700+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimilars and Follow-on Biologics R&D Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter’s Five Forces, SWOT Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and sub-markets
By Type of Manufacturing
• In-House
• Contract
By Type
• Monoclonal Antibodies
• Fusion Proteins
• Insulin
• Erythropoietin
• Granulocyte-Colony Stimulating Factor
• Interferon
• Growth Hormones
• Fertility Hormones
• Others
By Application
• Blood Disorders
• Oncology Diseases
• Chronic & Autoimmune Diseases
• Growth Hormone Deficiencies
• Others
By Technology
• RDNA Technology
• Mab Technology
• Bioassay Technology
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 14 leading national markets:
By Region
• North America
- U.S.
- Canada
• Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
• Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
• Latin America
- Brazil
- Mexico
- Rest of Latin America
• Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Leading companies and the potential for market growth
Overall world revenue for Biosimilars and Follow-on Biologics R&D Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Biosimilars and Follow-on Biologics R&D Market report helps you
In summary, our 570+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Biosimilars and Follow-on Biologics R&D Market, with forecasts for Type of Manufacturing, Type, Application, and Technology, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 14 key national markets– See forecasts for the Biosimilars and Follow-on Biologics R&D market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 20 of the companies involved in the biosimilars and follow-on biologics R&D Market. Some of the company’s profiled in this report include 3SBio, Inc., AMEGA Biotech, Amgen Inc., Apotex, Inc., BIOCAD, Biocon Limited, Biogen, Inc., Celltrion Healthcare Co., Ltd., Coherus BioSciences, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Gedeon Richter PLC, Intas Pharmaceutical Ltd., Mabxience SA, Viatris Inc. (Mylan NV), Novartis AG, Pfizer Inc., Samsung Bioepis Co. Ltd., Stada Arzneimittel AG, and Teva Pharmaceutical among other prominent players.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Biosimilars and Follow-on Biologics R&D Market and leading companies. You will find data, trends, and predictions.
'
1. Report Overview
1.1 Introduction to Biosimilars and Follow-on Biologics R&D Market
1.2 Biosimilars and Follow-on Biologics Market Definition
1.3 Why You Should Read This Report
1.4 What This Report Delivers
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 COVID-19 Impact: Recovery Scenarios
1.7.2 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
2.1 Europe Leading the Worldwide Biosimilars Market
2.1.1 Emerging Biopharmaceutical Companies to Drive Biosimilars Market Growth Further Over the Next Decade
2.1.2 The EU as a Gateway to Global Expansion
2.1.3 Growing Demand to Strategize Healthcare Costs to Offer Lucrative Growth Opportunities for Market Players
3 Market Dynamics
3.1 Drivers
3.1.1 Incentivizing Providers to Adopt Biosimilars
3.1.2 Developed Regions Driving the Worldwide Biosimilars and Follow-on Biologics Market Growth
3.1.3 Biologics Patent Expiry Set to Open Fresh Revenue Pockets for Biosimilars Companies Over the Next Decade
3.1.4 Pricing Advantage of Biosimilars Comparison to Biologics Anticipated to Fuel Market Growth Through 2031
3.2 Restraints
3.2.1 High Cost Involvement, Uncertainty and Complexities in Manufacturing
3.2.2 Resistance from Biologics Manufacturers to Restrain Market Growth
3.2.3 Reluctance of Healthcare Providers to Switch to Biosimilars
3.3 Opportunities
3.3.1 Companies Can Use Information of Original Innovator thus Shorten Development & Approval Processes
3.3.2 Diversity in Approach Among the Authorities
3.4 Challenges
3.4.1 Lack of Incentive Strategies Across Geographies Anticipated to Challenge Market Growth
3.4.2 Building Trust Among End-Users is a Challenge for Market Growth
3.5 Trends
3.5.1 Regulatory Hurdles Slowing Down Access to Biosimilars
3.5.2 Vulnerability of Global Pharmaceutical Manufacturing Amid COVID-19
3.5.3 Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
3.5.4 Digital Transformations as a Key Enabler to Strengthen Research in Biosimilars Industry
3.6 Porter’s Five Forces Analysis
3.6.1 Buyer Power
3.6.2 Supplier Power
3.6.3 Competitive Rivalry
3.6.4 Threat of Substitute
3.6.5 Threat of New Entrants
3.7 PEST Analysis
3.7.1 Political Factors Impacting Biosimilars and Follow-on Biologics Market
3.7.2 Economic Factors Impacting Biosimilars and Follow-on Biologics Market
3.7.3 Social Factors Impacting Biosimilars and Follow-on Biologics Market
3.7.4 Technological Factors Impacting Biosimilars and Follow-on Biologics Market
4 Biosimilars and Follow-on Biologics Market by Type of Manufacturing
4.1 Introduction
4.2 In-House Segment Market Forecast, 2021-2031
4.2.1 COVID-19 Impact Recovery Scenarios (V, U, W, L)
4.3 CMOs Segment Market Forecast, 2021-2031
4.3.1 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5 Biosimilars and Follow-on Biologics Market by Type
5.1 Introduction
5.2 Monoclonal Antibodies Segment Market Forecast, 2021-2031
5.2.1 Monoclonal Antibodies Segment Market Overview
5.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.3 Fusion Proteins Segment Market Forecast, 2021-2031
5.3.1 Fusion Protein Segment Market Overview
5.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.4 Insulin Segment Market Forecast, 2021-2031
5.4.1 Insulin Segment Market Overview
5.4.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.5 Erythropoietin Segment Market Forecast, 2021-2031
5.5.1 Erythropoietin Segment Market Overview
5.5.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.6 Granulocyte-Colony Stimulating Factor Segment Market Forecast, 2021-2031
5.6.1 G-CSF Segment Market Overview
5.6.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.7 Interferon Segment Market Forecast, 2021-2031
5.7.1 Interferon Segment Market Overview
5.7.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.8 Growth Hormones Segment Market Forecast, 2021-2031
5.8.1 Growth Hormones Segment Market Overview
5.8.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.9 Fertility Hormones Segment Market Forecast, 2021-2031
5.9.1 Fertility Hormones Segment Market Overview
5.9.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.10 Others Segment Market Forecast, 2021-2031
5.10.1 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6 Biosimilars and Follow-on Biologics Market by Application
6.1 Blood Disorders Segment Market Forecast, 2021-2031
6.1.1 Blood Disorders Segment Market Overview
6.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6.2 Oncology Diseases Segment Market Forecast, 2021-2031
6.2.1 Oncology Diseases Segment Market Overview
6.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6.3 Chronic & Autoimmune Diseases Segment Market Forecast, 2021-2031
6.3.1 Chronic & Autoimmune Diseases Segment Market Overview
6.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6.4 Growth Hormone Deficiencies Segment Market Forecast, 2021-2031
6.4.1 Growth Hormone Deficiencies Segment Market Overview
6.4.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
6.5 Others Segment Market Forecast, 2021-2031
6.5.1 COVID-19 Impact Recovery Scenarios (V, U, W, L)
7 Biosimilars and Follow-on Biologics Market by Technology
7.1 rDNA Technology Segment Market Forecast, 2021-2031
7.1.1 rDNA Technology Segment Market Overview
7.1.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
7.2 mAb Technology Segment Market Forecast, 2021-2031
7.2.1 mAb Technology Segment Market Overview
7.2.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
7.3 Bioassay Technology Segment Market Forecast, 2021-2031
7.3.1 Bioassay Technology Segment Market Overview
7.3.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
8 Regional and Leading National Biosimilars and Follow-on Biologics Market Forecasts 2021-2031
8.1 Global Biosimilars and Follow-on Biologics Market by Region Forecast 2021-2031
8.2 COVID-19 Impact Recovery Scenarios (V, U, W, L)
9 North America Biosimilars and Follow-on Biologics Market
9.1 North America Biosimilars and Follow-on Biologics Market by Country, Forecast 2021-2031
9.2 North America Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing
9.3 North America Biosimilars and Follow-on Biologics Market Forecast by Type
9.4 North America Biosimilars and Follow-on Biologics Market Forecast by Application
9.5 North America Biosimilars and Follow-on Biologics Market Forecast by Technology
9.6 U.S. Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
9.6.1 United States is Just Beginning to Catch Up European Biosimilars Market
9.6.2 Rising Biosimilar Uptake to Fuel U.S. Biosimilars Market Growth
9.6.3 Advancements in Biosimilars Development and Approvals Across the United States to Fuel Market Growth
9.6.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): U.S. Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
9.7 Canada Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
9.7.1 Biosimilar Authorization Activity Across Canadian Region
9.7.2 Initiatives by Health Canada to Boost Canadian Biosimilars and Follow-on Biologics Market Over the Next Decade
9.7.3 Availability of Biosimilars in Oncology Treatment Landscape Driving Regional Growth
9.7.4 Canada Biosimilars and Follow-on Biologics Market Outlook
9.7.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): Canada Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10 Europe Biosimilars and Follow-on Biologics Market
10.1 Growing Prevalence of Lifestyle Diseases Anticipated to Fuel European Biosimilars Market Growth
10.2 Continued Benefits of Biosimilars to Offer Lucrative Growth Prospects in Long Term
10.3 Europe Biosimilars and Follow-on Biologics Market by Country, Forecast 2021-2031
10.4 Europe Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing
10.5 Europe Biosimilars and Follow-on Biologics Market Forecast by Type
10.6 Europe Biosimilars and Follow-on Biologics Market Forecast by Application
10.7 Europe Biosimilars and Follow-on Biologics Market Forecast by Technology
10.8 Germany Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.8.1 Biosimilars Have Been Accepted as an Important Component of Proper Medication Usage in Germany
10.8.2 Germany Intends to Switch to Biologics Pharmacies by August 2022 thus Jeopardising the Long-Term Viability of Biosimilars
10.8.3 Germany Biosimilars and Follow-on Biologics Market Outlook
10.8.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): Germany Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.9 UK Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.9.1 NHS Encouraging the Growth of Biosimilar Manufacturing in United Kingdom?
10.9.2 Despite Price Reduction, Biosimilar Medications are not Widely Used in Retail Settings?
10.9.3 UK Biosimilars and Follow-on Biologics Market Outlook
10.9.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): UK Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.10 France Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.10.1 How is the Biosimilar Pricing Situation Across France?
10.10.2 Initiatives taken by French Government to Offer Lucrative Growth Prospects for Biosimilars Manufacturers Over the Forecast Period
10.10.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): France Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.11 Italy Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.11.1 Italian Government Policies Anticipated to Fuel Development of Biosimilars Market Across the Region
10.11.2 Biosimilars to Help Reduce Price of Pharmaceuticals Across the Italian Region
10.11.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Italy Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.12 Spain Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.12.1 Spain Biosimilars and Follow-on Biologics Market Outlook
10.12.2 Budget Impact Analysis of Biosimilar Products in Spain
10.12.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Spain Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.13 Rest of Europe Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
10.13.1 Rest of Europe Biosimilars and Follow-on Biologics Market Outlook
10.13.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Europe Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11 Asia Pacific Biosimilars and Follow-on Biologics Market
11.1 Low Clinical Development Costs Coupled with Regulatory Framework Ease to Fuel Regional Growth
11.2 Indian Pharmaceutical Companies Have an Enormous Scope in the Biosimilars Market
11.3 Asia Pacific Biosimilars and Follow-on Biologics Market by Country, Forecast 2021-2031
11.4 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing
11.5 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Type
11.6 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Application
11.7 Asia Pacific Biosimilars and Follow-on Biologics Market Forecast by Technology
11.8 Japan Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.8.1 Biosimilars to Bolster Japanese Healthcare System Growth Over the Next Decade
11.8.2 Japan still has a slow growth in this sector compared to US and EU
11.8.3 Introduction of Biosimilars to Boost Regional Growth Through 2031
11.8.4 Ageing Japanese Population Demanding the Development of Biosimilars Over the Forecast Period
11.8.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): Japan Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.9 China Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.9.1 Significant Surge in Biosimilar Approvals Over The Past 3 Years to Drive Market Growth
11.9.2 Technological Advancements to Fuel Chinese Biosimilars Market Growth Over the Forecast Period
11.9.3 Expansion by Major Firms to Boost Chinese Biosimilars Market Growth Through 2031
11.9.4 Overcrowding of Chinese Market Has Led to the Withdrawal of International Players
11.9.5 COVID-19 Impact Recovery Scenarios (V, U, W, L): China Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.10 India Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.10.1 India Set to Become Sixth Largest Pharmaceutical Market By End of 2030
11.10.2 Renowned Pharmaceutical Companies Establishing Partnerships with Indian Pharma Companies
11.10.3 India Biosimilars and Follow-on Biologics Market Outlook
11.10.4 COVID-19 Impact Recovery Scenarios (V, U, W, L): India Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.11 Rest of Asia Pacific Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
11.11.1 South Korean Biopharma Companies Jostling to Capture Significant Share of Asia Pacific Biosimilars Market
11.11.2 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
12 Latin America Biosimilars and Follow-on Biologics Market
12.1 Latin America Biosimilars and Follow-on Biologics Market by Country, Forecast 2021-2031
12.2 Latin America Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing
12.3 Latin America Biosimilars and Follow-on Biologics Market Forecast by Type
12.4 Latin America Biosimilars and Follow-on Biologics Market Forecast by Application
12.5 Latin America Biosimilars and Follow-on Biologics Market Forecast by Technology
12.6 Brazil Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
12.6.1 Brazilian Biosimilars Regulations
12.6.2 Brazil Biosimilars and Follow-on Biologics Market Outlook
12.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Brazil Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
12.7 Mexico Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
12.7.1 Mexican Biosimilars Market to Offer Lucrative Growth Prospects Across Latin American Region
12.7.2 Mexico Biosimilars and Follow-on Biologics Market Outlook
12.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): Mexico Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
12.8 Rest of Latin America Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
12.8.1 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Latin America Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
13 Middle East and Africa Biosimilars and Follow-on Biologics Market
13.1 Middle East and Africa Biosimilars and Follow-on Biologics Market by Country, Forecast 2021-2031
13.2 MEA Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing
13.3 MEA Biosimilars and Follow-on Biologics Market Forecast by Type
13.4 MEA Biosimilars and Follow-on Biologics Market Forecast by Application
13.5 MEA Biosimilars and Follow-on Biologics Market Forecast by Technology
13.6 GCC Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
13.6.1 GCC Gearing Up to Take Big Jump on Biosimilars
13.6.2 Collaborations Among Pharmaceutical Firms Across GCC to Offer Lucrative Growth Prospects for Market Players Over the Forecast Period
13.6.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): GCC Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
13.7 South Africa Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
13.7.1 South African Evolving Demographic and Epidemiological Profile to Offer Lucrative Growth Prospects
13.7.2 Presence of Major Pharmaceutical Firms to Intensify Competition
13.7.3 COVID-19 Impact Recovery Scenarios (V, U, W, L): South Africa Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
13.8 Rest of Middle East and Africa Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
13.8.1 COVID-19 Impact Recovery Scenarios (V, U, W, L): Rest of Middle East and Africa Biosimilars and Follow-on Biologics Market Forecast, 2021-2031
14 Company Profiles
14.1 Biosimilars Company Ranking, 2020
14.2 3SBio, Inc.
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.2.4 Recent Developments
14.3 AMEGA Biotech
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Product Benchmarking
14.4 Amgen Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.4 Product Benchmarking
14.4.5 Recent Developments
14.5 Apotex, Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Product Benchmarking
14.6 BIOCAD
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Product Benchmarking
14.6.4 Recent Developments
14.7 Biocon Limited
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.4 Product Benchmarking
14.7.5 Recent Developments
14.8 Biogen, Inc.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.9 Celltrion Healthcare Co.,Ltd.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Recent Developments
14.10 Coherus BioSciences
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.10.4 Recent Developments
14.11 Dr. Reddy’s Laboratories Ltd.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.12 Eli Lilly and Company
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.4 Product Benchmarking
14.12.5 Recent Developments
14.13 Gedeon Richter PLC
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.13.4 Recent Developments
14.14 Intas Pharmaceutical Ltd.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.15 Mabxience SA
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Product Benchmarking
14.15.4 Recent Developments
14.16 Viatris Inc. (Mylan NV)
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.4 Product Benchmarking
14.16.5 Recent Developments
14.17 Novartis AG
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.4 Product Benchmarking
14.17.5 Recent Developments
14.18 Pfizer Inc.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.4 Product Benchmarking
14.18.5 Recent Developments
14.19 Samsung Bioepis Co. Ltd.
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Product Benchmarking
14.19.4 Recent Developments
14.20 Stada Arzneimittel AG
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.4 Product Benchmarking
14.20.5 Recent Developments
14.21 Teva Pharmaceutical
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.4 Product Benchmarking
14.21.5 Recent Developments
15 Conclusion and Recommendations
15.1 Concluding Remarks
15.2 Recommendations
15.3 Europe Leading the Global Biosimilars Market
List of Tables
Table 1 Global Biosimilars and Follow-on Biologics Market Snapshot, 2021 & 2031 (US$ million, CAGR %)
Table 2 Global Biosimilars and Follow-on Biologics Market Forecast by Type of Manufacturing, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 3 Global Biosimilars and Follow-on Biologics Market Forecast for In-House Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 4 Global Biosimilars and Follow-on Biologics Market Forecast for In-House Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 5 Global Biosimilars and Follow-on Biologics Market Forecast for In-House Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 6 Global Biosimilars and Follow-on Biologics Market Forecast for In-House Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 7 Global Biosimilars and Follow-on Biologics Market Forecast for In-House Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 8 Global Biosimilars and Follow-on Biologics Market Forecast for CMOs Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 9 Global Biosimilars and Follow-on Biologics Market Forecast for CMOs Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 10 Global Biosimilars and Follow-on Biologics Market Forecast for CMOs Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 11 Global Biosimilars and Follow-on Biologics Market Forecast for CMOs Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 12 Global Biosimilars and Follow-on Biologics Market Forecast for CMOs Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 13 Global Biosimilars and Follow-on Biologics Market Forecast by Type, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 14 Global Biosimilars and Follow-on Biologics Market Forecast for Monoclonal Antibodies Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 15 Global Biosimilars and Follow-on Biologics Market Forecast for Monoclonal Antibodies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 16 Global Biosimilars and Follow-on Biologics Market Forecast for Monoclonal Antibodies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 17 Global Biosimilars and Follow-on Biologics Market Forecast for Monoclonal Antibodies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 18 Global Biosimilars and Follow-on Biologics Market Forecast for Monoclonal Antibodies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 19 Global Biosimilars and Follow-on Biologics Market Forecast for Fusion Proteins Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 20 Global Biosimilars and Follow-on Biologics Market Forecast for Fusion Proteins Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 21 Global Biosimilars and Follow-on Biologics Market Forecast for Fusion Proteins Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 22 Global Biosimilars and Follow-on Biologics Market Forecast for Fusion Proteins Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 23 Global Biosimilars and Follow-on Biologics Market Forecast for Fusion Proteins Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 24 Global Biosimilars and Follow-on Biologics Market Forecast for Insulin Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 25 Global Biosimilars and Follow-on Biologics Market Forecast for Insulin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 26 Global Biosimilars and Follow-on Biologics Market Forecast for Insulin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 27 Global Biosimilars and Follow-on Biologics Market Forecast for Insulin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 28 Global Biosimilars and Follow-on Biologics Market Forecast for Insulin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 29 Global Biosimilars and Follow-on Biologics Market Forecast for Erythropoietin Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 30 Global Biosimilars and Follow-on Biologics Market Forecast for Erythropoietin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 31 Global Biosimilars and Follow-on Biologics Market Forecast for Erythropoietin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 32 Global Biosimilars and Follow-on Biologics Market Forecast for Erythropoietin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 33 Global Biosimilars and Follow-on Biologics Market Forecast for Erythropoietin Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 34 Global Biosimilars and Follow-on Biologics Market Forecast for Granulocyte-Colony Stimulating Factor Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 35 Global Biosimilars and Follow-on Biologics Market Forecast for Granulocyte-Colony Stimulating Factor Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 36 Global Biosimilars and Follow-on Biologics Market Forecast for Granulocyte-Colony Stimulating Factor Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 37 Global Biosimilars and Follow-on Biologics Market Forecast for Granulocyte-Colony Stimulating Factor Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 38 Global Biosimilars and Follow-on Biologics Market Forecast for Granulocyte-Colony Stimulating Factor Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 39 Global Biosimilars and Follow-on Biologics Market Forecast for Interferon Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 40 Global Biosimilars and Follow-on Biologics Market Forecast for Interferon Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 41 Global Biosimilars and Follow-on Biologics Market Forecast for Interferon Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 42 Global Biosimilars and Follow-on Biologics Market Forecast for Interferon Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 43 Global Biosimilars and Follow-on Biologics Market Forecast for Interferon Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 44 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 45 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 46 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 47 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 48 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 49 Global Biosimilars and Follow-on Biologics Market Forecast for Fertility Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 50 Global Biosimilars and Follow-on Biologics Market Forecast for Fertility Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 51 Global Biosimilars and Follow-on Biologics Market Forecast for Fertility Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 52 Global Biosimilars and Follow-on Biologics Market Forecast for Fertility Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 53 Global Biosimilars and Follow-on Biologics Market Forecast for Fertility Hormones Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 54 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 55 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 56 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 57 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 58 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 59 Global Biosimilars and Follow-on Biologics Market Forecast by Application, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 60 Global Biosimilars and Follow-on Biologics Market Forecast for Blood Disorders Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 61 Global Biosimilars and Follow-on Biologics Market Forecast for Blood Disorders Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 62 Global Biosimilars and Follow-on Biologics Market Forecast for Blood Disorders Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 63 Global Biosimilars and Follow-on Biologics Market Forecast for Blood Disorders Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 64 Global Biosimilars and Follow-on Biologics Market Forecast for Blood Disorders Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 65 Global Biosimilars and Follow-on Biologics Market Forecast for Oncology Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 66 Global Biosimilars and Follow-on Biologics Market Forecast for Oncology Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 67 Global Biosimilars and Follow-on Biologics Market Forecast for Oncology Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 68 Global Biosimilars and Follow-on Biologics Market Forecast for Oncology Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 69 Global Biosimilars and Follow-on Biologics Market Forecast for Oncology Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 70 Global Biosimilars and Follow-on Biologics Market Forecast for Chronic & Autoimmune Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 71 Global Biosimilars and Follow-on Biologics Market Forecast for Chronic & Autoimmune Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 72 Global Biosimilars and Follow-on Biologics Market Forecast for Chronic & Autoimmune Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 73 Global Biosimilars and Follow-on Biologics Market Forecast for Chronic & Autoimmune Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 74 Global Biosimilars and Follow-on Biologics Market Forecast for Chronic & Autoimmune Diseases Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 75 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormone Deficiencies Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 76 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormone Deficiencies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 77 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormone Deficiencies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 78 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormone Deficiencies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 79 Global Biosimilars and Follow-on Biologics Market Forecast for Growth Hormone Deficiencies Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 80 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 81 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 82 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 83 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 84 Global Biosimilars and Follow-on Biologics Market Forecast for Others Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 85 Global Biosimilars and Follow-on Biologics Market Forecast by Country, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 86 Global Biosimilars and Follow-on Biologics Market Forecast for rDNA Technology Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 87 Global Biosimilars and Follow-on Biologics Market Forecast for rDNA Technology Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "V" Shaped Recovery
Table 88 Global Biosimilars and Follow-on Biologics Market Forecast for rDNA Technology Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "U" Shaped Recovery
Table 89 Global Biosimilars and Follow-on Biologics Market Forecast for rDNA Technology Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "W" Shaped Recovery
Table 90 Global Biosimilars and Follow-on Biologics Market Forecast for rDNA Technology Segment, 2021-2031 (US$ mn, AGR%, CAGR%): "L" Shaped Recovery
Table 91 Global Biosimilars and Follow-on Biologics Market Forecast for Mab Technology Segment, 2021-2031 (US$ mn, AGR%, CAGR%)
Table 92 Global Biosimilars and Follow-on Biologics Market Forecast for Mab Technology Segment, 2021-2031 (US$ mn, AGR%
